Academic Innovation Leader and Experienced Scientist to Join C-Path’s PKD Consortium

Sorin Fedeles, Ph.D., MBA to serve as new Executive Director

TUCSON, Ariz., October 14, 2021 – Critical Path Institute (C-Path) today announced it has named Sorin Fedeles, Ph.D., MBA as Executive Director of its Polycystic Kidney Disease Outcomes Consortium (PKDOC), effective October 1, 2021.

Dr. Fedeles comes to C-Path after 12-plus years as a scientist and faculty at Yale University School of Medicine, where he led a program focused on identifying new targets and pharmacological avenues for the treatment of autosomal dominant polycystic kidney disease, which represents the leading genetic cause of kidney failure in the U.S.  With expertise in genetics, biomedical discovery/translational research and inter-disciplinary collaborations, his primary role will be providing operational and scientific leadership that guides development and implementation of strategic priorities aimed at achieving PKDOC’s mission.

Established in 2010, PKDOC serves as a convener, curator, and innovator in the PKD community to generate solutions that accelerate drug development to bring new therapies to patients in need. “We are delighted to have Sorin join our PKDOC team to advance the consortium’s important work,” said Senior Vice President of the Translational and Safety Sciences Program John-Michael Sauer, Ph.D. “His extensive and unique combination of experience will be pivotal in continuing momentum toward ensuring PKD patients have access to safe and effective drugs as quickly as possible.”

PKDOC operates with support from the U.S Food and Drug Administration and the Polycystic Kidney Disease Foundation. “As the only organization in the U.S. solely dedicated to finding treatments and a cure for polycystic kidney disease, we are thrilled to have Sorin join the PKDOC team as Executive Director,” said Chris Rusconi, Ph.D., Chief Research Officer of the Foundation and Co-director of PKDOC. “With his breadth of professional experience and long-standing commitment to PKD research, the consortium is positioned to make a profound impact in the field.”

Originally from Romania, Dr. Fedeles received his undergraduate degree in biochemistry and cell biology from Hampshire College (Massachusetts), and earned three graduate degrees from Yale University, including a Master of Science in biological & biomedical sciences, a Ph.D. in genetics, and an MBA in healthcare management.

Dr. Fedeles brings his understanding of the drug development process, including preclinical research and clinical trials, cross-functional leadership and expert knowledge of genetic kidney disorders to C-Path and PKDOC. “As an academic member of PKDOC for several years I have seen first-hand the transformative impact of the consortium and C-Path as a whole,” said Fedeles. “I am honored to have the opportunity to lead PKDOC as it cultivates collaborations and advances innovative projects to improve the lives of those living with PKD.”

For more information on C-Path’s PKD Outcomes Consortium, visit:

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 56.5% funded by FDA/HHS, totaling $16,749,891, and 43.5% funded by non-government source(s), totaling $12,895,366. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit


About C-Path

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit and


Media Contact:

Kissy Black

Posted in AZBio News.